← Back to Clinical Trials
Recruiting NCT05797649

NCT05797649 Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05797649
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Pleural Effusion
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2023-07-01
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2023-07-01 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).

Eligibility Criteria

Inclusion Criteria: * Patients hospitalized for heart failure and pleural effusion * Pleural tapping indicated for pleural fluid analysis. * Aged 18 years old or above Exclusion Criteria: * History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space. * History of surgical decortication or pleurodesis in the ipsilateral pleural space. * Ipsilateral thoracic or cardiac surgery in the past 3 months. * Failure to obtain informed consent due to the patient's refusal or cognitive impairment.

Contact & Investigator

Central Contact

Christopher Chan, MBChB

✉ christopherchan@cuhk.edu.hk

📞 35053396

Frequently Asked Questions

Who can join the NCT05797649 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pleural Effusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05797649 currently recruiting?

Yes, NCT05797649 is actively recruiting participants. Contact the research team at christopherchan@cuhk.edu.hk for enrollment information.

Where is the NCT05797649 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT05797649 clinical trial?

NCT05797649 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology